Cholangitis

Throughout 2025, the team at Liver Disease News has reported on the latest research and advances in care related to various rare and non-rare liver…

Galangin, a naturally occurring compound found in honey and certain plants, was shown to reduce inflammation and liver injury in a mouse model of…

The frequency of primary sclerosing cholangitis (PSC) in people with inflammatory bowel disease (IBD) is lower in Asian countries than in the West, according…

The experimental oral therapy linerixibat from GlaxoSmithKline (GSK) offers rapid and sustained relief from severe itch in adults with primary biliary cholangitis (PBC),…

Nebokitug, an experimental infusion therapy being developed by Chemomab Therapeutics for primary sclerosing cholangitis (PSC), reduces the inflammatory…

Liscure Biosciences has launched a Phase 2 clinical trial to test whether its experimental probiotic LB-P8 can improve gut health and reduce liver inflammation…

Up to three years of treatment with Gilead Sciences‘ Livdelzi (seladelpar) results in sustained reductions in itching and biomarkers of liver injury in adults…

The most recent assessment of liver stiffness best predicts the future risk of liver disease progression among adults with primary biliary cholangitis (PBC), regardless…

Oct. 29 is Global PSC Awareness Day, and advocates around the world are joining forces to shine a light on primary sclerosing cholangitis (PSC)…

AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to…